Peel Therapeutics, Inc.

SALT LAKE CITY, Nov. 1, 2023 /PRNewswire/ -- Peel Therapeutics, a clinical stage biotech company developing evolutionary based medicines, will present data on its lead clinical asset, PEEL-224, at two conferences this week. PEEL-224 is a small molecule nanoparticle engineered to improve delivery to tumors and avoid chemoresistance. PEEL-224 originates from Camptotheca acuminata, a toxin found in the Happy Tree from China. Camptothecin is a TOP1 inhibitor that interferes with DNA repair and kills damaged cells. Camptothecin has been used for thousands of years in Traditional Chinese medicine and more recently in irinotecan-based chemotherapy for solid tumors in children and adults. PEEL-224's modified TOP1 inhibitor payload and unique delivery system may offer clinical advantages to patients with solid tumors. Continue Reading Camptotheca acuminata, original source of TOP1 inhibitors. On Nov. 2, Dr. Robert Maki, medical oncologist at Memorial Sloan Kettering Cancer Center and Interim Medical Director at Peel Therapeutics, will present "An early phase study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PEEL-224 in patients with advanced solid tumors" during the Trials in Progress Poster Session at the Connective Tissue Oncology Society (CTOS) 2023 Annual Meeting in Dublin, Ireland. Dr. Maki will discuss PEEL-224-001, a first-in-human, dose escalation, repeat-dose, multi-center, open-label study in the United States. On Nov. 4, Dr. Aleah Caulin, VP of Nonclinical at Peel Therapeutics, will present "100% Complete Response to PEEL-224 in Combination with PD-1 Blockade in a Syngeneic Mouse Model of Colon Cancer" during the poster session at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego. Dr. Caulin will describe the results of combined PEEL-224 and PD-1 blockade in a syngeneic mouse model of colon cancer: Vehicle (0% Complete Response [CR]), PD-1 inhibitor only (30% CR), PEEL-224 only (80% CR), PEEL-224 + PD-1 inhibitor (100% CR). Based on these findings, PEEL-224 combined with immunotherapy may be a promising approach for difficult-to-treat tumors and translation to human clinical trials are being considered. "As a pediatric oncologist, I understand how important it is to develop drugs like PEEL-224 with the potential for decreased toxicity and increased efficacy," said Dr. Joshua Schiffman, CEO and Co-founder, Peel Therapeutics. "Peel's clinical trial is approaching what the team believes will be the recommended phase 2 dose with plans for expansion cohorts in GI malignancies and sarcoma. We are pleased by our continued progress and the efforts of our team to test if PEEL-224 will benefit patients in need." About Peel Therapeutics Peel Therapeutics is an evolutionary-inspired, clinical-stage biotech company that engineers evolutionary biology for patients with cancer and inflammation. The Peel team identifies how nature accomplishes the inconceivable in preventing or defeating disease. Using multidisciplinary scientific and drug development expertise, these findings are rapidly translated into new medicines. Peel Therapeutics pushes the limits of biology to develop highly effective and safe medicines that transcend the incremental. "Peel" is the Hebrew word for elephant, the company originates from the observation that elephants are naturally cancer resistant. Media Contact Liz Boten Evoke Canale for Peel Therapeutics [email protected] SOURCE PEEL Therapeutics

Peer-reviewed study offers first description of ongoing NETosis induction in Long COVID; provides insights into pathogenesis and can serve as a surrogate marker for persistent pathology Research emphasizes need to explore neutrophil-targeted therapies in acute and chronic COVID-19 SALT LAKE CITY, April 13, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced research conducted by the company has been published in The Journal of Thrombosis and Haemostasis. The study, NETosis Induction Reflects COVID-19 Severity and Long COVID: Insights from a Two-Center Patient Cohort Study in Israel, evaluated the ability of blood from Israeli patients with Long COVID to induce neutrophil extracellular traps (NETs) as a marker of ongoing inflammation. NETs are sticky webs of DNA released by activated immunes cells that contribute to immunothrombosis (mini-clots) and fibrosis. Peel scientists also correlated NETosis potential with acute disease severity in COVID-19. The study concluded that NET inhibitors may be a possible treatment approach for COVID-19 and recommended additional research to confirm findings. Peel Therapeutics is developing first-in-class Neutrophil Targeting Peptides (NTPs) – originating from natural NET inhibitors in newborns – to block inflammation leading to immunothrombosis and fibrosis. In this study, Peel researchers examined NETs among people with and without COVID-19 and measured NET induction during and after infection. The study concluded that increased NETosis induction can be detected in people with Long COVID, offering insight into the potential uses of NTPs and other NET inhibitors for the treatment of Long COVID. The study included 177 patients from 2 Israeli hospitals with acute COVID-19 infection (mild/moderate or severe/critical) or convalescent COVID-19 (recovered or Long COVID), along with 54 non-COVID controls. People who experienced symptoms of Long COVID maintained higher NETosis induction compared to recovered convalescent patients. Dr. Kimberly Martinod, Assistant Professor in Cardiovascular Sciences at KU Leuven, runs a NET research laboratory that studies clotting and fibrosis in heart failure and is co-author on the paper. Dr. Martinod remarked, "Measuring NETs in blood samples is challenging. The Peel team quantified the ability of patient blood to form NETs instead of measuring fragments of NETs which can be complicated by their rapid degradation – especially in COVID-19 where this is unbalanced. This study demonstrates the increased ability of blood from patients with acute and ongoing COVID-19 to induce NETs in healthy neutrophils. This reflects ongoing inflammation that may trigger excessive NET release, even weeks after the initial infection has cleared." Peel CEO and Co-founder, Dr. Joshua Schiffman, stated, "This study offers a new target for COVID patients suffering from ongoing inflammation. The potential use of our NTPs in acute and chronic COVID further validates Peel's ability to unlock evolutionary biology for cancer and inflammation. Our preclinical research lays the groundwork for scientists and clinicians to understand NTP's potential to treat inflammatory diseases, improve health outcomes, and in this case, offer hope to patients with Long COVID." The study can be accessed via the Journal of Thrombosis and Haemostasis. About Peel Therapeutics Peel Therapeutics is an evolutionary-inspired, clinical-stage biotech company that engineers nature better than evolution intended. Our scientists search for nature's super abilities where evolutionary biology accomplished the inconceivable in preventing or defeating disease. We then apply drug development expertise to rapidly translate this evolutionary biology into medicines. The company is advancing a therapeutic pipeline to treat a spectrum of devastating conditions, with a near-term focus on cancer and inflammation. At Peel Therapeutics, we push the limits of biology to develop highly effective and safe medicines for patients. "Peel" is the Hebrew word for elephant, our company originates from the natural cancer resistance found in elephants.

SALT LAKE CITY, Feb. 23, 2023 /PRNewswire/ -- Peel Therapeutics, an evolutionary-inspired, clinical-stage biotech company, announced recent company updates to support its drug development programs in cancer and inflammation. The company recently secured $9M in funding, bringing its total seed financing to $36M. The company also expanded its Board of Directors to support and guide the company through this rapid growth stage. "Peel Therapeutics made meaningful strides over the past year – including initiating a Phase 1 clinical trial in advanced solid tumors to evaluate PEEL-224 – our small molecule that targets topoisomerase 1 activity and has been engineered to avoid chemoresistance. We are pleased to capitalize on these efforts, to serve those with cancer and inflammation," said Joshua Schiffman, M.D., CEO and Co-founder of Peel Therapeutics. "As we advance Peel's therapeutic pipeline to treat a spectrum of devastating conditions, we apply the team's scientific and medical expertise to rapidly translate evolutionary biology into treatments." New Financing Secured Peel Therapeutics has raised a total of $36M in seed financing, plus over $3M in non-dilutive capital including National Institutes of Health Small Business Innovation Research and Small Business Technology Transfer funding. Most recently, the company closed a $9M SAFE financing round which will be used to advance clinical and pre-clinical programs. Board of Directors Expanded Ryan Watts, CEO, Denali Therapeutics and Carin Canale-Theakston, CEO, Evoke Canale joined the Peel Therapeutics Board of Directors, comprised of experts in medicine, science, technology, and business. Ryan Watts is CEO and Co-founder of Denali Therapeutics. Under his leadership, Denali has advanced multiple therapeutic candidates into clinical testing for Parkinson's Disease, Alzheimer's Disease, and Amyotrophic Lateral Sclerosis (ALS). Watts has led efforts to raise significant capital to advance Denali's pipeline and has been instrumental in forging partnerships to accelerate the discovery and development of medicines for neurodegeneration. "I am excited to be a part of Peel Therapeutics and their ground-breaking approach to engineer molecules in nature into drugs with significant impact for patients with cancer and inflammation." Watts says, "Joining as a Director is an opportunity to participate in Peel's next stage of growth." Carin Canale-Theakston is a life science executive with more than 25 years of experience helping companies navigate business and communications. She has shaped strategies for more than 500 life science companies and has experience with companies of all sizes and stages, ranging from emerging biopharma startups and venture capital firms, to major diagnostic companies, to several of the world's largest pharmaceutical companies. Canale-Theakston comments, "Peel has impressed me with its meaningful nonclinical data coupled with their passion for helping patients, I am eager to work with the Peel team to help advance evolution-inspired drugs to the clinic." About Peel Therapeutics Peel Therapeutics is an evolutionary-inspired, clinical-stage biotech company that engineers nature better than evolution intended. Our team searches for nature's super abilities where evolutionary biology accomplished the inconceivable in preventing or defeating disease. We then apply multidisciplinary scientific and drug development expertise to rapidly translate this evolutionary biology into medicines. The company is advancing a therapeutic pipeline to treat a spectrum of devastating conditions, with a near-term focus on cancer and inflammation. At Peel Therapeutics, we push the limits of biology to develop highly effective and safe medicines for patients that transcend the incremental. "Peel" is the Hebrew word for elephant, our company originates from the natural cancer resistance found in elephants. View original content to download multimedia: SOURCE PEEL Therapeutics